Pacira BioSciences
PCRX
233 hedge funds and large institutions have $1.21B invested in Pacira BioSciences in 2025 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 84 increasing their positions, 77 reducing their positions, and 32 closing their positions.
220% more call options, than puts
Call options by funds: $7.02M | Put options by funds: $2.2M
9% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 77
0.17% less ownership
Funds ownership: 109.34% → 109.17% (-0.17%)
1% less funds holding
Funds holding: 235 → 233 (-2)
3% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 32
4% less capital invested
Capital invested by funds: $1.26B → $1.21B (-$49.7M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$22.9M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$15.3M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$14.2M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$13M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$33.5M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$27.9M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
-$9.99M |
| 4 |
JP Morgan Chase
New York
|
-$7.83M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$7.06M |
PCRX Hedge Fund Activity: Q2 2025 in Review
233 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2025, worth a combined $1.21B — down 4% from $1.26B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of PCRX and 31 opened new positions — a net loss of 1 holder — while 77 trimmed existing stakes and 84 added.
The largest buyer was Polar Capital Holdings, opening a new position worth an estimated $22.9M. The largest seller was Citadel Advisors, exiting entirely with an estimated $33.5M sold.
- 233 institutional investors held Pacira BioSciences (PCRX) as of Q2 2025, down from 235 in Q1 2025.
- Funds reported $1.21B of Pacira BioSciences stock for Q2 2025, down 4% quarter-over-quarter.
- 31 funds opened new Pacira BioSciences positions in Q2 2025 and 32 closed out, a net change of -1 holder.
- The largest Pacira BioSciences buyer in Q2 2025 was Polar Capital Holdings, an estimated $22.9M added.
- The largest Pacira BioSciences seller in Q2 2025 was Citadel Advisors, an estimated $33.5M sold.
Based on aggregated 13F filings for Q2 2025.